| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Transgenic Mice by 
-Difluoromethylornithine Accompanied by Marked Hair Follicle Degeneration and Hair Loss
Departments of Human Oncology [D. L. W., K. J. N., A. K. V.] and Pathology and Laboratory Medicine [T. D. O.], Medical School, University of Wisconsin, Madison, Wisconsin 53762, and Veterans Administration Hospital, Madison, Wisconsin 53705 [T. D. O.]
The role of 12-O-tetradecanoylphorbol-13-acetate (TPA)-stimulated polyamine biosynthesis in the development of metastatic squamous cell carcinoma (mSCC) in protein kinase C 
(PKC) transgenic mice was determined. TPA treatment induced epidermal ornithine decarboxylase (ODC) activity and putrescine levels approximately 3–4-fold more in PKC transgenic mice than their wild-type littermates. Development of mSCC by the 7,12-dimethylbenz(a)anthracene (100 nmol)-TPA (5 nmol) protocol in PKC transgenic mice was completely prevented by administration of the suicide inhibitor of ODC 
-difluoromethylornithine (DFMO, 0.5% w/v) in the drinking water during TPA promotion. However, DFMO treatment led to marked hair loss in PKC transgenic mice. DFMO treatment-associated hair loss in PKC transgenic mice was accompanied by a decrease in the number of intact hair follicles. These results indicate that TPA-induced ODC activity and the resultant accumulation of putrescine in PKC transgenic mice are linked to growth and maintenance of hair follicles, and the development of mSCC. Severe hair loss observed in PKC transgenic mice on DFMO during skin tumor promotion has not been reported before in the prevention of cancer in other animal models or in human cancer prevention trials.
This article has been cited by other articles:
|
|
 |
|
  F. Wu, D. Grossenbacher, and H. Gehring New transition state-based inhibitor for human ornithine decarboxylase inhibits growth of tumor cells Mol. Cancer Ther., June 1, 2007; 6(6): 1831 - 1839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Gerdes, M. Myakishev, N. A. Frost, V. Rishi, J. Moitra, A. Acharya, M. R. Levy, S.-w. Park, A. Glick, S. H. Yuspa, et al. Activator protein-1 activity regulates epithelial tumor cell identity. Cancer Res., August 1, 2006; 66(15): 7578 - 7588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Feith, S. Origanti, P. L. Shoop, S. Sass-Kuhn, and L. M. Shantz Tumor suppressor activity of ODC antizyme in MEK-driven skin tumorigenesis Carcinogenesis, May 1, 2006; 27(5): 1090 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Chu, J. M. Koomen, R. Kobayashi, and C. A. O'Brian Identification of an Inactivating Cysteine Switch in Protein Kinase C{varepsilon}, a Rational Target for the Design of Protein Kinase C{varepsilon}-Inhibitory Cancer Therapeutics Cancer Res., November 15, 2005; 65(22): 10478 - 10485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shivji, S. Burger, C. A. Moncada, A. B. Clarkson Jr., and S. Merali Effect of Nicotine on Lung S-Adenosylmethionine and Development of Pneumocystis Pneumonia J. Biol. Chem., April 15, 2005; 280(15): 15219 - 15228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Feith, D. K. Bol, J. M. Carboni, M. J. Lynch, S. Sass-Kuhn, P. L. Shoop, and L. M. Shantz Induction of Ornithine Decarboxylase Activity Is a Necessary Step for Mitogen-Activated Protein Kinase Kinase-Induced Skin Tumorigenesis Cancer Res., January 15, 2005; 65(2): 572 - 578. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
